Articles tagged with Positron Emission Tomography
A clinical trial found that using PET imaging to guide chemotherapy significantly increases remission rates and reduces toxic side effects in advanced Hodgkin lymphoma patients. The study showed a promising approach to tailor treatment to individual patients, leading to a potential new standard of care.
Researchers found that combining computed bioconductance (CB) with positron emission tomography (PET) before biopsy can improve the detection of potentially cancerous lung lesions. This non-invasive diagnostic tool may aid in the accurate evaluation of suspicious lung lesions.
A recent study published in Neurology found that maintaining mental activity can slow the onset of Alzheimer's symptoms in people without a family history of the disease. For those with the APOE4 gene, continued learning and intellectual activity in middle age can lower amyloid plaque levels.
A national look at PET scan use for lung and esophageal cancer survivors found widespread variation between hospitals, with some using scans eight times more often than others. The study suggests that this approach doesn't improve survival rates and is being inappropriately used at many hospitals.
A study published in the JNCI: Journal of the National Cancer Institute found that PET scans did not improve two-year survival rates for lung and esophageal cancer patients. The researchers suggest potential overuse of PET scans in detecting recurrence, warranting efforts to decrease unnecessary utilization.
Researchers at Uppsala University have developed a new PET imaging method that uses monoclonal antibodies to provide more precise information on the brain than traditional radioactive tracers. The method has shown high specificity and can monitor the progression of Alzheimer's disease, allowing for better assessment of medication effects.
A recent study shows that a PET/CT scan using F-18-DCFBC is significantly more effective in detecting metastatic prostate cancer than other detection methods. The radiotracer targets prostate-specific membrane antigen, which is expressed in the majority of prostate cancers and associated with metastatic spread.
The new risk management plan aims to prioritize data quality, reduce costs, and decrease attrition rates in imaging biomarker-driven trials. By identifying risks at trial initiation and allocating resources effectively, the framework can help minimize variability and ensure reproducibility of data.
Researchers have successfully implemented time-of-flight PET scanning technology, reducing the radiation dose for cancer patients and staff by up to 30%. This has allowed an additional 100 scans per year at Central Manchester University Hospitals.
The Berkeley Lab team is developing electronics that will send data from the scanner's detectors to a computer, converting it into a three-dimensional image of the patient. This new scanner will have half a million detectors, reducing a patient's radiation dose by a factor of 40 and scanning time from 20 minutes to just 30 seconds.
A UC Davis research team has been awarded $15.5 million to develop the world's first total-body PET scanner, which could revolutionize cancer tracking and treatment. The new technology allows for simultaneous imaging of the entire body, reducing radiation dose by a factor of 40 and scanning time from 20 minutes to just 30 seconds.
A new Lund University study found that both amyloid PET imaging and cerebrospinal fluid samples are effective methods for detecting early-stage Alzheimer's disease. The two methods identified approximately 90% of patients with the disease, making them equally viable options.
A novel radiopharmaceutical probe has been developed to detect blood clots anywhere in the body using whole-body PET scans. The probe can distinguish recently formed clots from older ones and reveal clot composition, which can determine treatment response.
Research published in the International Journal of Biomedical Engineering and Technology reveals a wavelet transform approach that improves medical imaging. The technique boosts the signal-to-noise ratio and reduces artifacts, allowing for earlier disease detection and diagnosis.
Researchers emphasize the need to improve brain imaging accuracy for dementia diagnosis and progression prediction. MRI scans and PET scans show promise, but current methods are not sensitive or accurate enough for widespread adoption.
Researchers developed a molecular imaging biomarker that detects fast-growing primary prostate cancer and distinguishes it from benign prostate lesions. The new PSMA-based PET imaging technique was more specific than MR imaging for detecting clinically significant high-grade prostate cancer lesions.
Researchers have developed a new probe that can detect blood clots in any part of the body using positron emission tomography (PET). The probe, called FBP8, contains copper-64 and has shown promise in detecting blood clots in rats, paving the way for future human trials.
A new approach to visualize glucose uptake activity in single living cells has been developed by Columbia University researchers. This technique uses stimulated Raman scattering imaging with a small alkyne tag to generate a strong Raman signal, allowing for high-sensitivity imaging of glucose uptake at the cellular level.
Dr. Hartmuth Kolb was recognized for his pioneering research on neurofibrillary tangles (NFTs) and Alzheimer's disease (AD). His PET imaging tracers showed promise in evaluating NFT pathology, holding potential for disease diagnosis and monitoring.
A study found that 86% of women with early-stage breast cancer in Ontario underwent imaging to detect metastatic cancer, despite international guidelines recommending against it. The use of advanced imaging increased and varied by geographic region and hospital type, highlighting a need for improved knowledge translation strategies.
Researchers have developed a cloud-based software that analyzes and standardizes PET imaging data, allowing for earlier and more accurate diagnoses of Alzheimer's disease. The program uses machine learning to compare patients' scans with normal and abnormal scans, providing consistent results and quantifying PET data accurately.
A new theranostic agent, I-124 PEG-AVP0458, has shown promise in targeting both ovarian and prostate cancer cells for imaging and treatment. The drug compound attaches itself to the targeted tumor sites via positron emission tomography (PET) scanners, enabling personalized cancer therapy.
Scientists have developed a novel PET tracer that can pinpoint thrombi throughout the body with over 97% accuracy. The tracer, Cu-64 FBP8, targets fibrin in blood clots and reflects thrombus age, enabling clinicians to choose more effective treatments.
A new technique combines dynamic PET imaging with parametric tumor mapping to detect tumors and metastases throughout the body, providing quantitative evaluation and improved contrast. This method has the potential to be used for early diagnosis and more accurate prognosis of various cancers.
A novel PET technique tracks microglial activation in response to endotoxin, shedding light on neuroinflammatory diseases like Alzheimer's and depression. The study's findings could lead to new drug treatments by targeting immune dysfunction.
A specialized PET tracer has been developed to visualize the function of nerve cells that lead to neuronal loss and cognitive decline in neurodegenerative diseases. The tracer binds to a transporter of the neurotransmitter acetylcholine, allowing for the quantification of cholinergic neuron loss and its effects on cognition.
Research shows amyloid PET scans improve diagnosis and treatment outcomes for Alzheimer's patients, especially when used after an indeterminate FDG-PET scan. The study found that 17% of patients who received an amyloid scan experienced statistically significant improvements in cognition over a two-year follow-up.
A new molecular imaging agent has been developed to detect prostate cancer that has spread to other tissues. The agent targets the PSMA enzyme, which is associated with prostate cancer, and has shown high accuracy in detecting disease sites, including those not identified by conventional methods.
A new study found that PET/CT scans are highly sensitive for detecting relapsed non-Hodgkin lymphoma, with a sensitivity rate of 95.1%. This breakthrough has significant implications for patient care, as early diagnosis can lead to improved treatment outcomes and longer survival rates.
Townsend's contributions to nuclear medicine have been transformative, introducing 3D PET imaging and the combined PET/CT scanner. His work has improved the signal-to-noise of reconstructed images without increasing detector material cost.
Phelps was recognized for his contributions to nuclear medicine and molecular imaging, including the invention of PET scanners. His work has improved outcomes for patients with cancer, neurological disorders, and cardiovascular disease.
Researchers developed new PET probes using labeled antibody fragments to visualize tumors in mice. These probes could provide more information about tumors and help doctors choose treatment options.
Researchers developed new PET probes composed of labeled antibody fragments that can detect pancreatic cancer tumors too small to be detected with conventional methods. These probes show promise for targeted imaging and tracking the delivery of drugs.
Two studies analyze amyloid prevalence among adults of varying ages and its association with cognitive impairment. The findings indicate that key risk factors for Alzheimer's disease are also risk factors for amyloid positivity in cognitively normal persons.
A novel approach harnessing positron emission tomography (PET) imaging identifies areas of immune cell activity associated with inflammation or tumor development. This method offers a potential breakthrough in diagnostics and monitoring efficacy of cancer therapies.
A new imaging tool found a strikingly similar pattern of abnormal protein deposits in the brains of retired NFL players with concussions, which may help identify brain disorders like CTE. The study also shows differences in brain imaging patterns between concussed athletes and healthy individuals.
A study of over 1,200 cognitively normal individuals aged 30-95 found that men experienced worse memory decline and lower hippocampal volume than women, while APOE ?4 carriers had greater amyloid accumulation from age 70 onwards.
The study found that cardiac PET/CT imaging diagnosed heart problems with certainty 88% of the time, while SPECT imaging gave a clear diagnosis only 30% of the time. This technology reduces unnecessary invasive procedures and radiation exposure by a factor of 10.
Researchers found PET/MR to be superior in diagnosing foot pain causes, providing more diagnostic information and higher certainty than PET/CT. This non-invasive method offers an important tool for sensitive diagnosis of foot pathologies.
Advanced medical imaging increases diagnostic confidence and facilitates rapid diagnoses, leading to better clinical decisions. Primary care physicians perceive imaging as crucial for quality patient care, particularly for sicker patients.
Research finds accumulated brain damage linked to memory deficits and mood regulation in former NFL players, supporting calls for improved athlete protection from concussion. PET scans show concentrated zones of high translocator protein levels, indicating brain injury and potential long-term neurological risk.
University at Buffalo researchers have designed a nanoparticle that can be detected by six medical imaging techniques, including CT scanning, PET scanning, and photoacoustic imaging. This technology has the potential to provide doctors with clearer pictures of patients' organs and tissues, enabling faster diagnosis and treatment.
Researchers used positron emission tomography (PET) and computed tomography (CT) imaging to monitor antibiotic treatment effects in TB-infected monkeys and humans. Changes in PET/CT scans over time accurately predicted treatment outcomes, potentially shortening clinical trials and saving resources.
Researchers found changes in metabolic activity of key brain region after successful treatment with psychodynamic therapy. Patients who completed therapy had a greater than 50 percent reduction in depression symptoms.
Research suggests that pathological gamblers have a different response to the brain's opioid system, resulting in reduced feelings of euphoria compared to healthy individuals. This altered response may contribute to the addictive nature of gambling.
A new technique using bioimpedance measurement reduces image degradation caused by respiratory motion during PET scans, enabling more accurate detection of cancers and heart conditions. This improved imaging quality can lead to better diagnosis reliability and treatment response monitoring.
A new MRI technique called arterial spin labeling (ASL) can detect signs of cognitive decline in the brain even before symptoms appear. The technique measures brain perfusion and has the potential to serve as a biomarker for very early diagnosis of preclinical dementia.
A new experimental PET tracer effectively diagnoses chronic traumatic encephalopathy (CTE) while patients are still alive. The technology differentiates CTE from other forms of dementia, enabling estimates of prevalence and risk. This breakthrough improves diagnosis and treatment for athletes and others exposed to repeated head trauma.
Recent EORTC Imaging Group review highlights MRI and PET's potential for early detection of bone metastases and monitoring treatment response. The study emphasizes the need to overcome current limitations, such as those related to imaging techniques' sensitivity and specificity.
A PET study found that acupuncture at Yongquan acupoints induced stronger neuronal activity than sham acupoints, suggesting a potential mechanism for improving patients with DOC. The putamen, cingulate cortex, frontal lobe, and cerebellum were involved in conscious thought.
Researchers used PET imaging to study Tongxinluo's neuroprotective effects in rats. The study found that Tongxinluo reduced brain damage after middle cerebral artery occlusion, highlighting its potential as a treatment for acute stroke.
A new imaging agent has been developed for functional imaging of the intestine, potentially leading to better diagnosis and treatment of gut diseases. The agent uses a combination of photoacoustic imaging and positron emission tomography to provide high-definition images of the intestine in relation to the entire body.
Research trials report associations between decreased odor identification and loss of brain cell function, as well as beta-amyloid buildup in the eye with progression to Alzheimer's. Early detection is crucial for intervention and prevention, with promising results suggesting potential methods for early detection in a research setting.
Researchers developed a non-invasive imaging technique to track beta cell status in type 1 diabetes patients. The PET scan detects the amount of radiotracer in the pancreas, indicating the overall amount or volume of active beta cells present.
A new antibody-based molecular imaging agent has been developed to target the HER3 receptor in breast cancer, which may lead to better diagnosis and treatment of high-risk cases. This approach could also help identify patients who would benefit from additional therapies.
A novel F-18 labeled tracer, F-18 THK5117, selectively binds to tau/neurofibrillary tangles in Alzheimer's brains. This study demonstrates the potential for F-18 THK5117 to develop new anti-dementia drugs.
Siegel's work on PET has led to a major advance in nuclear medicine science, with a focus on evidence-based clinical trials and widespread acceptance of imaging studies. He is recognized for his visionary leadership in developing scientific methodology.
Researchers used SPECT and PET systems to detect inflammation involved in osteoarthritis, giving doctors a clear read on chronic pain and possible joint destruction. Radiolabeled anti-FAP antibodies showed significantly increased imaging agent uptake in inflamed joints.
Researchers can conduct five different imaging studies in one scan with the Opti-SPECT/PET/CT system, providing comprehensive data on anatomy and physiological processes. The device allows for minimally invasive studies with a single dose of anesthesia, enabling scientists to develop new drug discovery methods.
A new study reveals that PET/MR imaging is highly effective in detecting coronary artery disease, outperforming traditional SPECT methods. The hybrid technique provides a comprehensive view of the heart, combining anatomical and functional information for more accurate diagnoses.